nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—CYP2D6—Carteolol—glaucoma	0.085	0.159	CbGbCtD
Vemurafenib—CYP1A2—Betaxolol—glaucoma	0.0697	0.13	CbGbCtD
Vemurafenib—CYP2D6—Betaxolol—glaucoma	0.0574	0.107	CbGbCtD
Vemurafenib—CYP2D6—Methazolamide—glaucoma	0.0435	0.0811	CbGbCtD
Vemurafenib—CYP3A4—Pilocarpine—glaucoma	0.041	0.0764	CbGbCtD
Vemurafenib—CYP1A2—Clonidine—glaucoma	0.0382	0.0712	CbGbCtD
Vemurafenib—CYP2D6—Timolol—glaucoma	0.037	0.069	CbGbCtD
Vemurafenib—CYP3A4—Brinzolamide—glaucoma	0.0322	0.0599	CbGbCtD
Vemurafenib—CYP2D6—Clonidine—glaucoma	0.0315	0.0587	CbGbCtD
Vemurafenib—CYP3A4—Dorzolamide—glaucoma	0.0311	0.0579	CbGbCtD
Vemurafenib—CYP3A4—Methazolamide—glaucoma	0.0277	0.0516	CbGbCtD
Vemurafenib—CYP3A4—Acetazolamide—glaucoma	0.0221	0.0412	CbGbCtD
Vemurafenib—CYP3A4—Clonidine—glaucoma	0.02	0.0373	CbGbCtD
Vemurafenib—Etoricoxib—PTGS2—glaucoma	0.0022	1	CrCbGaD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Brimonidine—glaucoma	0.000557	0.00185	CcSEcCtD
Vemurafenib—Pruritus—Latanoprost—glaucoma	0.000554	0.00184	CcSEcCtD
Vemurafenib—Rash—Diclofenamide—glaucoma	0.000554	0.00184	CcSEcCtD
Vemurafenib—Diarrhoea—Methazolamide—glaucoma	0.000553	0.00184	CcSEcCtD
Vemurafenib—Headache—Diclofenamide—glaucoma	0.00055	0.00183	CcSEcCtD
Vemurafenib—Cough—Dorzolamide—glaucoma	0.000549	0.00182	CcSEcCtD
Vemurafenib—Cough—Travoprost—glaucoma	0.000546	0.00181	CcSEcCtD
Vemurafenib—Vomiting—Carbachol—glaucoma	0.000545	0.00181	CcSEcCtD
Vemurafenib—Rash—Carbachol—glaucoma	0.000541	0.0018	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Apraclonidine—glaucoma	0.00054	0.00179	CcSEcCtD
Vemurafenib—Dermatitis—Carbachol—glaucoma	0.00054	0.00179	CcSEcCtD
Vemurafenib—Fatigue—Apraclonidine—glaucoma	0.00054	0.00179	CcSEcCtD
Vemurafenib—Cough—Brinzolamide—glaucoma	0.000539	0.00179	CcSEcCtD
Vemurafenib—Headache—Carbachol—glaucoma	0.000537	0.00178	CcSEcCtD
Vemurafenib—Weight decreased—Betaxolol—glaucoma	0.000536	0.00178	CcSEcCtD
Vemurafenib—Arthralgia—Dorzolamide—glaucoma	0.000535	0.00178	CcSEcCtD
Vemurafenib—Constipation—Apraclonidine—glaucoma	0.000535	0.00178	CcSEcCtD
Vemurafenib—Infection—Brimonidine—glaucoma	0.000534	0.00177	CcSEcCtD
Vemurafenib—Arthralgia—Travoprost—glaucoma	0.000533	0.00177	CcSEcCtD
Vemurafenib—Myalgia—Travoprost—glaucoma	0.000533	0.00177	CcSEcCtD
Vemurafenib—Nausea—Carteolol—glaucoma	0.000531	0.00176	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Travoprost—glaucoma	0.000529	0.00176	CcSEcCtD
Vemurafenib—Headache—Levobunolol—glaucoma	0.000529	0.00176	CcSEcCtD
Vemurafenib—Infestation NOS—Betaxolol—glaucoma	0.000529	0.00176	CcSEcCtD
Vemurafenib—Infestation—Betaxolol—glaucoma	0.000529	0.00176	CcSEcCtD
Vemurafenib—Nervous system disorder—Brimonidine—glaucoma	0.000527	0.00175	CcSEcCtD
Vemurafenib—Myalgia—Brinzolamide—glaucoma	0.000526	0.00175	CcSEcCtD
Vemurafenib—Arthralgia—Brinzolamide—glaucoma	0.000526	0.00175	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Bimatoprost—glaucoma	0.000524	0.00174	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Brinzolamide—glaucoma	0.000523	0.00174	CcSEcCtD
Vemurafenib—Skin disorder—Brimonidine—glaucoma	0.000522	0.00173	CcSEcCtD
Vemurafenib—Nausea—Diclofenamide—glaucoma	0.000522	0.00173	CcSEcCtD
Vemurafenib—Cough—Pilocarpine—glaucoma	0.000518	0.00172	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Betaxolol—glaucoma	0.000518	0.00172	CcSEcCtD
Vemurafenib—Dizziness—Latanoprost—glaucoma	0.000518	0.00172	CcSEcCtD
Vemurafenib—Vomiting—Methazolamide—glaucoma	0.000514	0.00171	CcSEcCtD
Vemurafenib—Anaphylactic shock—Dorzolamide—glaucoma	0.000513	0.0017	CcSEcCtD
Vemurafenib—Rash—Methazolamide—glaucoma	0.00051	0.00169	CcSEcCtD
Vemurafenib—Dermatitis—Methazolamide—glaucoma	0.000509	0.00169	CcSEcCtD
Vemurafenib—Eye disorder—Clonidine—glaucoma	0.000509	0.00169	CcSEcCtD
Vemurafenib—Nausea—Carbachol—glaucoma	0.000509	0.00169	CcSEcCtD
Vemurafenib—Infection—Travoprost—glaucoma	0.000508	0.00169	CcSEcCtD
Vemurafenib—Headache—Methazolamide—glaucoma	0.000507	0.00168	CcSEcCtD
Vemurafenib—Cardiac disorder—Clonidine—glaucoma	0.000506	0.00168	CcSEcCtD
Vemurafenib—Arthralgia—Pilocarpine—glaucoma	0.000506	0.00168	CcSEcCtD
Vemurafenib—Myalgia—Pilocarpine—glaucoma	0.000506	0.00168	CcSEcCtD
Vemurafenib—Hypotension—Brimonidine—glaucoma	0.000502	0.00167	CcSEcCtD
Vemurafenib—Nausea—Levobunolol—glaucoma	0.000501	0.00167	CcSEcCtD
Vemurafenib—Infection—Brinzolamide—glaucoma	0.000501	0.00166	CcSEcCtD
Vemurafenib—Nervous system disorder—Travoprost—glaucoma	0.000501	0.00166	CcSEcCtD
Vemurafenib—Skin disorder—Travoprost—glaucoma	0.000496	0.00165	CcSEcCtD
Vemurafenib—Nervous system disorder—Brinzolamide—glaucoma	0.000495	0.00164	CcSEcCtD
Vemurafenib—Angiopathy—Clonidine—glaucoma	0.000495	0.00164	CcSEcCtD
Vemurafenib—Rash—Latanoprost—glaucoma	0.000494	0.00164	CcSEcCtD
Vemurafenib—Dermatitis—Latanoprost—glaucoma	0.000493	0.00164	CcSEcCtD
Vemurafenib—Mediastinal disorder—Clonidine—glaucoma	0.000491	0.00163	CcSEcCtD
Vemurafenib—Headache—Latanoprost—glaucoma	0.00049	0.00163	CcSEcCtD
Vemurafenib—Skin disorder—Brinzolamide—glaucoma	0.00049	0.00163	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Brimonidine—glaucoma	0.00049	0.00163	CcSEcCtD
Vemurafenib—Decreased appetite—Acetazolamide—glaucoma	0.000487	0.00162	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Acetazolamide—glaucoma	0.000483	0.00161	CcSEcCtD
Vemurafenib—Fatigue—Acetazolamide—glaucoma	0.000483	0.0016	CcSEcCtD
Vemurafenib—Infection—Pilocarpine—glaucoma	0.000482	0.0016	CcSEcCtD
Vemurafenib—Alopecia—Clonidine—glaucoma	0.000482	0.0016	CcSEcCtD
Vemurafenib—Nausea—Methazolamide—glaucoma	0.00048	0.0016	CcSEcCtD
Vemurafenib—Hypotension—Dorzolamide—glaucoma	0.00048	0.00159	CcSEcCtD
Vemurafenib—Hypotension—Travoprost—glaucoma	0.000477	0.00159	CcSEcCtD
Vemurafenib—Erythema—Clonidine—glaucoma	0.000474	0.00158	CcSEcCtD
Vemurafenib—Hypotension—Brinzolamide—glaucoma	0.000471	0.00157	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Dorzolamide—glaucoma	0.000468	0.00155	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Travoprost—glaucoma	0.000466	0.00155	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Brimonidine—glaucoma	0.000464	0.00154	CcSEcCtD
Vemurafenib—Fatigue—Brimonidine—glaucoma	0.000463	0.00154	CcSEcCtD
Vemurafenib—Hypersensitivity—Apraclonidine—glaucoma	0.000461	0.00153	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Brinzolamide—glaucoma	0.00046	0.00153	CcSEcCtD
Vemurafenib—Hypotension—Pilocarpine—glaucoma	0.000453	0.0015	CcSEcCtD
Vemurafenib—Asthenia—Apraclonidine—glaucoma	0.000449	0.00149	CcSEcCtD
Vemurafenib—Decreased appetite—Dorzolamide—glaucoma	0.000446	0.00148	CcSEcCtD
Vemurafenib—Eye disorder—Betaxolol—glaucoma	0.000443	0.00147	CcSEcCtD
Vemurafenib—Pruritus—Apraclonidine—glaucoma	0.000443	0.00147	CcSEcCtD
Vemurafenib—Body temperature increased—Acetazolamide—glaucoma	0.000443	0.00147	CcSEcCtD
Vemurafenib—Fatigue—Dorzolamide—glaucoma	0.000442	0.00147	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Pilocarpine—glaucoma	0.000442	0.00147	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Travoprost—glaucoma	0.000441	0.00147	CcSEcCtD
Vemurafenib—Fatigue—Travoprost—glaucoma	0.000441	0.00146	CcSEcCtD
Vemurafenib—Cardiac disorder—Betaxolol—glaucoma	0.00044	0.00146	CcSEcCtD
Vemurafenib—Decreased appetite—Brinzolamide—glaucoma	0.000439	0.00146	CcSEcCtD
Vemurafenib—Weight decreased—Timolol—glaucoma	0.000438	0.00146	CcSEcCtD
Vemurafenib—Constipation—Travoprost—glaucoma	0.000437	0.00145	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Brinzolamide—glaucoma	0.000436	0.00145	CcSEcCtD
Vemurafenib—Asthenia—Bimatoprost—glaucoma	0.000435	0.00145	CcSEcCtD
Vemurafenib—Fatigue—Brinzolamide—glaucoma	0.000435	0.00144	CcSEcCtD
Vemurafenib—Angiopathy—Betaxolol—glaucoma	0.000431	0.00143	CcSEcCtD
Vemurafenib—Pruritus—Bimatoprost—glaucoma	0.000429	0.00143	CcSEcCtD
Vemurafenib—Diarrhoea—Apraclonidine—glaucoma	0.000428	0.00142	CcSEcCtD
Vemurafenib—Mediastinal disorder—Betaxolol—glaucoma	0.000428	0.00142	CcSEcCtD
Vemurafenib—Chills—Betaxolol—glaucoma	0.000426	0.00141	CcSEcCtD
Vemurafenib—Decreased appetite—Pilocarpine—glaucoma	0.000422	0.0014	CcSEcCtD
Vemurafenib—Alopecia—Betaxolol—glaucoma	0.000419	0.00139	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Pilocarpine—glaucoma	0.000419	0.00139	CcSEcCtD
Vemurafenib—Constipation—Pilocarpine—glaucoma	0.000415	0.00138	CcSEcCtD
Vemurafenib—Cough—Clonidine—glaucoma	0.000414	0.00138	CcSEcCtD
Vemurafenib—Dizziness—Apraclonidine—glaucoma	0.000414	0.00137	CcSEcCtD
Vemurafenib—Erythema—Betaxolol—glaucoma	0.000413	0.00137	CcSEcCtD
Vemurafenib—Malnutrition—Betaxolol—glaucoma	0.000413	0.00137	CcSEcCtD
Vemurafenib—Body temperature increased—Dorzolamide—glaucoma	0.000406	0.00135	CcSEcCtD
Vemurafenib—Dysgeusia—Betaxolol—glaucoma	0.000405	0.00134	CcSEcCtD
Vemurafenib—Arthralgia—Clonidine—glaucoma	0.000404	0.00134	CcSEcCtD
Vemurafenib—Asthenia—Acetazolamide—glaucoma	0.000402	0.00133	CcSEcCtD
Vemurafenib—Dizziness—Bimatoprost—glaucoma	0.000401	0.00133	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	0.000401	0.00133	CcSEcCtD
Vemurafenib—Vomiting—Apraclonidine—glaucoma	0.000398	0.00132	CcSEcCtD
Vemurafenib—Hypersensitivity—Brimonidine—glaucoma	0.000396	0.00131	CcSEcCtD
Vemurafenib—Dermatitis—Apraclonidine—glaucoma	0.000394	0.00131	CcSEcCtD
Vemurafenib—Headache—Apraclonidine—glaucoma	0.000392	0.0013	CcSEcCtD
Vemurafenib—Asthenia—Brimonidine—glaucoma	0.000386	0.00128	CcSEcCtD
Vemurafenib—Infection—Clonidine—glaucoma	0.000385	0.00128	CcSEcCtD
Vemurafenib—Body temperature increased—Pilocarpine—glaucoma	0.000383	0.00127	CcSEcCtD
Vemurafenib—Diarrhoea—Acetazolamide—glaucoma	0.000383	0.00127	CcSEcCtD
Vemurafenib—Rash—Bimatoprost—glaucoma	0.000383	0.00127	CcSEcCtD
Vemurafenib—Dermatitis—Bimatoprost—glaucoma	0.000382	0.00127	CcSEcCtD
Vemurafenib—Oedema peripheral—Timolol—glaucoma	0.000382	0.00127	CcSEcCtD
Vemurafenib—Connective tissue disorder—Timolol—glaucoma	0.000381	0.00127	CcSEcCtD
Vemurafenib—Pruritus—Brimonidine—glaucoma	0.00038	0.00126	CcSEcCtD
Vemurafenib—Headache—Bimatoprost—glaucoma	0.00038	0.00126	CcSEcCtD
Vemurafenib—Nervous system disorder—Clonidine—glaucoma	0.00038	0.00126	CcSEcCtD
Vemurafenib—Hypersensitivity—Dorzolamide—glaucoma	0.000378	0.00126	CcSEcCtD
Vemurafenib—Hypersensitivity—Travoprost—glaucoma	0.000376	0.00125	CcSEcCtD
Vemurafenib—Skin disorder—Clonidine—glaucoma	0.000376	0.00125	CcSEcCtD
Vemurafenib—Nausea—Apraclonidine—glaucoma	0.000372	0.00123	CcSEcCtD
Vemurafenib—Hypersensitivity—Brinzolamide—glaucoma	0.000372	0.00123	CcSEcCtD
Vemurafenib—Dizziness—Acetazolamide—glaucoma	0.00037	0.00123	CcSEcCtD
Vemurafenib—Asthenia—Dorzolamide—glaucoma	0.000368	0.00122	CcSEcCtD
Vemurafenib—Asthenia—Travoprost—glaucoma	0.000367	0.00122	CcSEcCtD
Vemurafenib—Pruritus—Dorzolamide—glaucoma	0.000363	0.00121	CcSEcCtD
Vemurafenib—Eye disorder—Timolol—glaucoma	0.000362	0.0012	CcSEcCtD
Vemurafenib—Asthenia—Brinzolamide—glaucoma	0.000362	0.0012	CcSEcCtD
Vemurafenib—Hypotension—Clonidine—glaucoma	0.000362	0.0012	CcSEcCtD
Vemurafenib—Pruritus—Travoprost—glaucoma	0.000361	0.0012	CcSEcCtD
Vemurafenib—Cough—Betaxolol—glaucoma	0.00036	0.0012	CcSEcCtD
Vemurafenib—Nausea—Bimatoprost—glaucoma	0.00036	0.0012	CcSEcCtD
Vemurafenib—Cardiac disorder—Timolol—glaucoma	0.00036	0.00119	CcSEcCtD
Vemurafenib—Hypersensitivity—Pilocarpine—glaucoma	0.000357	0.00119	CcSEcCtD
Vemurafenib—Pruritus—Brinzolamide—glaucoma	0.000357	0.00119	CcSEcCtD
Vemurafenib—Vomiting—Acetazolamide—glaucoma	0.000356	0.00118	CcSEcCtD
Vemurafenib—Dizziness—Brimonidine—glaucoma	0.000355	0.00118	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Clonidine—glaucoma	0.000353	0.00117	CcSEcCtD
Vemurafenib—Angiopathy—Timolol—glaucoma	0.000352	0.00117	CcSEcCtD
Vemurafenib—Arthralgia—Betaxolol—glaucoma	0.000352	0.00117	CcSEcCtD
Vemurafenib—Myalgia—Betaxolol—glaucoma	0.000352	0.00117	CcSEcCtD
Vemurafenib—Diarrhoea—Dorzolamide—glaucoma	0.000351	0.00117	CcSEcCtD
Vemurafenib—Headache—Acetazolamide—glaucoma	0.000351	0.00116	CcSEcCtD
Vemurafenib—Diarrhoea—Travoprost—glaucoma	0.00035	0.00116	CcSEcCtD
Vemurafenib—Mediastinal disorder—Timolol—glaucoma	0.000349	0.00116	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	0.000349	0.00116	CcSEcCtD
Vemurafenib—Asthenia—Pilocarpine—glaucoma	0.000348	0.00116	CcSEcCtD
Vemurafenib—Diarrhoea—Brinzolamide—glaucoma	0.000345	0.00115	CcSEcCtD
Vemurafenib—Pruritus—Pilocarpine—glaucoma	0.000343	0.00114	CcSEcCtD
Vemurafenib—Alopecia—Timolol—glaucoma	0.000343	0.00114	CcSEcCtD
Vemurafenib—Dizziness—Dorzolamide—glaucoma	0.000339	0.00113	CcSEcCtD
Vemurafenib—Rash—Brimonidine—glaucoma	0.000339	0.00113	CcSEcCtD
Vemurafenib—Dermatitis—Brimonidine—glaucoma	0.000338	0.00112	CcSEcCtD
Vemurafenib—Dizziness—Travoprost—glaucoma	0.000338	0.00112	CcSEcCtD
Vemurafenib—Erythema—Timolol—glaucoma	0.000337	0.00112	CcSEcCtD
Vemurafenib—Malnutrition—Timolol—glaucoma	0.000337	0.00112	CcSEcCtD
Vemurafenib—Headache—Brimonidine—glaucoma	0.000337	0.00112	CcSEcCtD
Vemurafenib—Decreased appetite—Clonidine—glaucoma	0.000337	0.00112	CcSEcCtD
Vemurafenib—Infection—Betaxolol—glaucoma	0.000335	0.00111	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Clonidine—glaucoma	0.000334	0.00111	CcSEcCtD
Vemurafenib—Fatigue—Clonidine—glaucoma	0.000334	0.00111	CcSEcCtD
Vemurafenib—Dizziness—Brinzolamide—glaucoma	0.000334	0.00111	CcSEcCtD
Vemurafenib—Nausea—Acetazolamide—glaucoma	0.000333	0.0011	CcSEcCtD
Vemurafenib—Diarrhoea—Pilocarpine—glaucoma	0.000332	0.0011	CcSEcCtD
Vemurafenib—Constipation—Clonidine—glaucoma	0.000331	0.0011	CcSEcCtD
Vemurafenib—Nervous system disorder—Betaxolol—glaucoma	0.000331	0.0011	CcSEcCtD
Vemurafenib—Dysgeusia—Timolol—glaucoma	0.00033	0.0011	CcSEcCtD
Vemurafenib—Skin disorder—Betaxolol—glaucoma	0.000327	0.00109	CcSEcCtD
Vemurafenib—Vomiting—Dorzolamide—glaucoma	0.000326	0.00108	CcSEcCtD
Vemurafenib—Rash—Dorzolamide—glaucoma	0.000324	0.00107	CcSEcCtD
Vemurafenib—Dermatitis—Dorzolamide—glaucoma	0.000323	0.00107	CcSEcCtD
Vemurafenib—Rash—Travoprost—glaucoma	0.000322	0.00107	CcSEcCtD
Vemurafenib—Dermatitis—Travoprost—glaucoma	0.000322	0.00107	CcSEcCtD
Vemurafenib—Headache—Dorzolamide—glaucoma	0.000321	0.00107	CcSEcCtD
Vemurafenib—Vomiting—Brinzolamide—glaucoma	0.000321	0.00107	CcSEcCtD
Vemurafenib—Dizziness—Pilocarpine—glaucoma	0.000321	0.00106	CcSEcCtD
Vemurafenib—Headache—Travoprost—glaucoma	0.00032	0.00106	CcSEcCtD
Vemurafenib—Nausea—Brimonidine—glaucoma	0.000319	0.00106	CcSEcCtD
Vemurafenib—Rash—Brinzolamide—glaucoma	0.000318	0.00106	CcSEcCtD
Vemurafenib—Dermatitis—Brinzolamide—glaucoma	0.000318	0.00106	CcSEcCtD
Vemurafenib—Headache—Brinzolamide—glaucoma	0.000316	0.00105	CcSEcCtD
Vemurafenib—Hypotension—Betaxolol—glaucoma	0.000315	0.00105	CcSEcCtD
Vemurafenib—Vomiting—Pilocarpine—glaucoma	0.000308	0.00102	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Betaxolol—glaucoma	0.000307	0.00102	CcSEcCtD
Vemurafenib—Body temperature increased—Clonidine—glaucoma	0.000306	0.00102	CcSEcCtD
Vemurafenib—Rash—Pilocarpine—glaucoma	0.000306	0.00102	CcSEcCtD
Vemurafenib—Dermatitis—Pilocarpine—glaucoma	0.000305	0.00101	CcSEcCtD
Vemurafenib—Nausea—Dorzolamide—glaucoma	0.000305	0.00101	CcSEcCtD
Vemurafenib—Headache—Pilocarpine—glaucoma	0.000304	0.00101	CcSEcCtD
Vemurafenib—Nausea—Travoprost—glaucoma	0.000303	0.00101	CcSEcCtD
Vemurafenib—Nausea—Brinzolamide—glaucoma	0.0003	0.000995	CcSEcCtD
Vemurafenib—Cough—Timolol—glaucoma	0.000294	0.000978	CcSEcCtD
Vemurafenib—Decreased appetite—Betaxolol—glaucoma	0.000293	0.000973	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Betaxolol—glaucoma	0.000291	0.000967	CcSEcCtD
Vemurafenib—Fatigue—Betaxolol—glaucoma	0.000291	0.000965	CcSEcCtD
Vemurafenib—Constipation—Betaxolol—glaucoma	0.000288	0.000958	CcSEcCtD
Vemurafenib—Nausea—Pilocarpine—glaucoma	0.000288	0.000957	CcSEcCtD
Vemurafenib—Myalgia—Timolol—glaucoma	0.000287	0.000954	CcSEcCtD
Vemurafenib—Arthralgia—Timolol—glaucoma	0.000287	0.000954	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	0.000285	0.000948	CcSEcCtD
Vemurafenib—Hypersensitivity—Clonidine—glaucoma	0.000285	0.000948	CcSEcCtD
Vemurafenib—Asthenia—Clonidine—glaucoma	0.000278	0.000923	CcSEcCtD
Vemurafenib—Anaphylactic shock—Timolol—glaucoma	0.000275	0.000915	CcSEcCtD
Vemurafenib—Pruritus—Clonidine—glaucoma	0.000274	0.00091	CcSEcCtD
Vemurafenib—Infection—Timolol—glaucoma	0.000274	0.000909	CcSEcCtD
Vemurafenib—Nervous system disorder—Timolol—glaucoma	0.00027	0.000897	CcSEcCtD
Vemurafenib—Skin disorder—Timolol—glaucoma	0.000268	0.000889	CcSEcCtD
Vemurafenib—Body temperature increased—Betaxolol—glaucoma	0.000267	0.000885	CcSEcCtD
Vemurafenib—Diarrhoea—Clonidine—glaucoma	0.000265	0.00088	CcSEcCtD
Vemurafenib—Hypotension—Timolol—glaucoma	0.000257	0.000855	CcSEcCtD
Vemurafenib—Dizziness—Clonidine—glaucoma	0.000256	0.00085	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Timolol—glaucoma	0.000251	0.000833	CcSEcCtD
Vemurafenib—Hypersensitivity—Betaxolol—glaucoma	0.000248	0.000825	CcSEcCtD
Vemurafenib—Vomiting—Clonidine—glaucoma	0.000246	0.000818	CcSEcCtD
Vemurafenib—Rash—Clonidine—glaucoma	0.000244	0.000811	CcSEcCtD
Vemurafenib—Dermatitis—Clonidine—glaucoma	0.000244	0.00081	CcSEcCtD
Vemurafenib—Headache—Clonidine—glaucoma	0.000243	0.000806	CcSEcCtD
Vemurafenib—Asthenia—Betaxolol—glaucoma	0.000242	0.000803	CcSEcCtD
Vemurafenib—Decreased appetite—Timolol—glaucoma	0.000239	0.000795	CcSEcCtD
Vemurafenib—Pruritus—Betaxolol—glaucoma	0.000239	0.000792	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Timolol—glaucoma	0.000238	0.00079	CcSEcCtD
Vemurafenib—Fatigue—Timolol—glaucoma	0.000237	0.000789	CcSEcCtD
Vemurafenib—Diarrhoea—Betaxolol—glaucoma	0.000231	0.000766	CcSEcCtD
Vemurafenib—Nausea—Clonidine—glaucoma	0.00023	0.000764	CcSEcCtD
Vemurafenib—Dizziness—Betaxolol—glaucoma	0.000223	0.00074	CcSEcCtD
Vemurafenib—Body temperature increased—Timolol—glaucoma	0.000218	0.000723	CcSEcCtD
Vemurafenib—Vomiting—Betaxolol—glaucoma	0.000214	0.000712	CcSEcCtD
Vemurafenib—Rash—Betaxolol—glaucoma	0.000213	0.000706	CcSEcCtD
Vemurafenib—Dermatitis—Betaxolol—glaucoma	0.000212	0.000705	CcSEcCtD
Vemurafenib—Headache—Betaxolol—glaucoma	0.000211	0.000701	CcSEcCtD
Vemurafenib—Hypersensitivity—Timolol—glaucoma	0.000203	0.000674	CcSEcCtD
Vemurafenib—Nausea—Betaxolol—glaucoma	0.0002	0.000665	CcSEcCtD
Vemurafenib—Asthenia—Timolol—glaucoma	0.000198	0.000656	CcSEcCtD
Vemurafenib—Pruritus—Timolol—glaucoma	0.000195	0.000647	CcSEcCtD
Vemurafenib—Diarrhoea—Timolol—glaucoma	0.000188	0.000626	CcSEcCtD
Vemurafenib—Dizziness—Timolol—glaucoma	0.000182	0.000605	CcSEcCtD
Vemurafenib—Vomiting—Timolol—glaucoma	0.000175	0.000582	CcSEcCtD
Vemurafenib—Rash—Timolol—glaucoma	0.000174	0.000577	CcSEcCtD
Vemurafenib—Dermatitis—Timolol—glaucoma	0.000173	0.000576	CcSEcCtD
Vemurafenib—Headache—Timolol—glaucoma	0.000173	0.000573	CcSEcCtD
Vemurafenib—Nausea—Timolol—glaucoma	0.000164	0.000543	CcSEcCtD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—PTGS2—glaucoma	8.74e-05	0.000546	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—CDKN1B—glaucoma	8.72e-05	0.000544	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—CTSA—glaucoma	8.7e-05	0.000543	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—CDKN1B—glaucoma	8.67e-05	0.000541	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—CDKN1B—glaucoma	8.65e-05	0.000539	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—BAD—glaucoma	8.61e-05	0.000537	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—CDKN1B—glaucoma	8.61e-05	0.000537	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—C1QB—glaucoma	8.47e-05	0.000529	CbGpPWpGaD
Vemurafenib—RAF1—Senescence and Autophagy in Cancer—TP53—glaucoma	8.4e-05	0.000524	CbGpPWpGaD
Vemurafenib—BRAF—MAPK Signaling Pathway—TP53—glaucoma	8.34e-05	0.00052	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—RPTOR—glaucoma	8.3e-05	0.000518	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—SOD1—glaucoma	8.28e-05	0.000517	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—CDKN1B—glaucoma	8.28e-05	0.000517	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CA5A—glaucoma	8.25e-05	0.000515	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—NARFL—glaucoma	8.25e-05	0.000515	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—CA2—glaucoma	8.22e-05	0.000513	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—SLC6A13—glaucoma	8.17e-05	0.00051	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—OPN4—glaucoma	8.15e-05	0.000509	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—glaucoma	8.1e-05	0.000505	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NCK2—glaucoma	8.04e-05	0.000502	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	8.03e-05	0.000501	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	8.03e-05	0.000501	CbGpPWpGaD
Vemurafenib—CYP1A2—Biological oxidations—CYP1B1—glaucoma	7.94e-05	0.000496	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—SOD1—glaucoma	7.93e-05	0.000495	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CA1—glaucoma	7.91e-05	0.000493	CbGpPWpGaD
Vemurafenib—CYP1A2—Metapathway biotransformation—CYP1B1—glaucoma	7.83e-05	0.000489	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—CDKN1B—glaucoma	7.8e-05	0.000486	CbGpPWpGaD
Vemurafenib—CYP3A4—Biological oxidations—GSTT1—glaucoma	7.69e-05	0.00048	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CTSA—glaucoma	7.66e-05	0.000478	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HEYL—glaucoma	7.58e-05	0.000473	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—TXN—glaucoma	7.55e-05	0.000471	CbGpPWpGaD
Vemurafenib—CYP2D6—Biological oxidations—GSTM1—glaucoma	7.5e-05	0.000468	CbGpPWpGaD
Vemurafenib—ALB—Platelet degranulation—VEGFA—glaucoma	7.44e-05	0.000464	CbGpPWpGaD
Vemurafenib—ALB—Folate Metabolism—TNF—glaucoma	7.43e-05	0.000464	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—CTSA—glaucoma	7.42e-05	0.000463	CbGpPWpGaD
Vemurafenib—CYP2D6—Metapathway biotransformation—GSTM1—glaucoma	7.39e-05	0.000461	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PTGFR—glaucoma	7.34e-05	0.000458	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CA2—glaucoma	7.23e-05	0.000451	CbGpPWpGaD
Vemurafenib—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—glaucoma	7.09e-05	0.000442	CbGpPWpGaD
Vemurafenib—RAF1—TGF-beta Signaling Pathway—TP53—glaucoma	6.99e-05	0.000436	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NARFL—glaucoma	6.99e-05	0.000436	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CA5A—glaucoma	6.99e-05	0.000436	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—glaucoma	6.94e-05	0.000433	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor—TNF—glaucoma	6.94e-05	0.000433	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—VEGFA—glaucoma	6.92e-05	0.000432	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—VEGFA—glaucoma	6.89e-05	0.00043	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—HDAC9—glaucoma	6.84e-05	0.000427	CbGpPWpGaD
Vemurafenib—RAF1—Disease—HDAC9—glaucoma	6.75e-05	0.000421	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—HDAC9—glaucoma	6.69e-05	0.000418	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—MMP2—glaucoma	6.69e-05	0.000417	CbGpPWpGaD
Vemurafenib—ALB—Folate Metabolism—TP53—glaucoma	6.55e-05	0.000409	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—TNF—glaucoma	6.54e-05	0.000408	CbGpPWpGaD
Vemurafenib—CYP1A2—Biological oxidations—GSTM1—glaucoma	6.35e-05	0.000396	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—SMO—glaucoma	6.27e-05	0.000391	CbGpPWpGaD
Vemurafenib—CYP1A2—Metapathway biotransformation—GSTM1—glaucoma	6.26e-05	0.000391	CbGpPWpGaD
Vemurafenib—CYP3A4—Biological oxidations—CYP1B1—glaucoma	6.13e-05	0.000382	CbGpPWpGaD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—VEGFA—glaucoma	6.13e-05	0.000382	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—MMP1—glaucoma	6.05e-05	0.000377	CbGpPWpGaD
Vemurafenib—CYP3A4—Metapathway biotransformation—CYP1B1—glaucoma	6.05e-05	0.000377	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—CDKN1B—glaucoma	6e-05	0.000374	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—SLC6A1—glaucoma	5.98e-05	0.000373	CbGpPWpGaD
Vemurafenib—ALB—Selenium Micronutrient Network—TNF—glaucoma	5.91e-05	0.000368	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	5.9e-05	0.000368	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—CAV1—glaucoma	5.8e-05	0.000362	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—TXN—glaucoma	5.79e-05	0.000361	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—TP53—glaucoma	5.77e-05	0.00036	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—FN1—glaucoma	5.76e-05	0.00036	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—RPTOR—glaucoma	5.74e-05	0.000358	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—C3—glaucoma	5.66e-05	0.000353	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TGFB2—glaucoma	5.63e-05	0.000351	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NCK2—glaucoma	5.56e-05	0.000347	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—FN1—glaucoma	5.52e-05	0.000344	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—C3—glaucoma	5.44e-05	0.000339	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—BCL2L1—glaucoma	5.42e-05	0.000338	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NARFL—glaucoma	5.39e-05	0.000336	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CA5A—glaucoma	5.39e-05	0.000336	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SMO—glaucoma	5.35e-05	0.000334	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—APOE—glaucoma	5.28e-05	0.00033	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CDKN2B—glaucoma	5.25e-05	0.000327	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—CAV1—glaucoma	5.23e-05	0.000327	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	5.2e-05	0.000325	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—TXN—glaucoma	5.09e-05	0.000318	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—MMP9—glaucoma	5.03e-05	0.000314	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—BAD—glaucoma	4.91e-05	0.000306	CbGpPWpGaD
Vemurafenib—CYP3A4—Biological oxidations—GSTM1—glaucoma	4.9e-05	0.000306	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NTRK2—glaucoma	4.89e-05	0.000305	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CA1—glaucoma	4.88e-05	0.000304	CbGpPWpGaD
Vemurafenib—CYP3A4—Metapathway biotransformation—GSTM1—glaucoma	4.83e-05	0.000302	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—MMP2—glaucoma	4.77e-05	0.000298	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HDAC9—glaucoma	4.73e-05	0.000295	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CTSA—glaucoma	4.72e-05	0.000295	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—BAD—glaucoma	4.72e-05	0.000294	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—VEGFA—glaucoma	4.51e-05	0.000282	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—GSTT1—glaucoma	4.49e-05	0.00028	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CA2—glaucoma	4.46e-05	0.000278	CbGpPWpGaD
Vemurafenib—BRAF—Disease—MTHFR—glaucoma	4.4e-05	0.000275	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—NOS3—glaucoma	4.39e-05	0.000274	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	4.36e-05	0.000272	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	4.36e-05	0.000272	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—SOD1—glaucoma	4.27e-05	0.000266	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NGFR—glaucoma	4.2e-05	0.000262	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—EDN1—glaucoma	4.13e-05	0.000258	CbGpPWpGaD
Vemurafenib—BRAF—Disease—APOE—glaucoma	4.1e-05	0.000256	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CAV1—glaucoma	4.06e-05	0.000253	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CA1—glaucoma	4.03e-05	0.000251	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NTRK1—glaucoma	3.99e-05	0.000249	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—GSTT1—glaucoma	3.95e-05	0.000246	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CTSA—glaucoma	3.9e-05	0.000243	CbGpPWpGaD
Vemurafenib—BRAF—Disease—BAD—glaucoma	3.82e-05	0.000238	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL1A—glaucoma	3.75e-05	0.000234	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SMO—glaucoma	3.7e-05	0.000231	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CA2—glaucoma	3.68e-05	0.00023	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CDKN2B—glaucoma	3.68e-05	0.000229	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CDKN2B—glaucoma	3.63e-05	0.000227	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	3.62e-05	0.000226	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—C3—glaucoma	3.61e-05	0.000225	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CDKN2B—glaucoma	3.6e-05	0.000225	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—MMP9—glaucoma	3.59e-05	0.000224	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—CYP1B1—glaucoma	3.58e-05	0.000223	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—ABCA1—glaucoma	3.58e-05	0.000223	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—EDN1—glaucoma	3.53e-05	0.00022	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—CDKN1B—glaucoma	3.42e-05	0.000213	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CA1—glaucoma	3.41e-05	0.000213	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NTRK2—glaucoma	3.38e-05	0.000211	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CTSA—glaucoma	3.3e-05	0.000206	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—VEGFA—glaucoma	3.3e-05	0.000206	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—C3—glaucoma	3.3e-05	0.000206	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CDKN1B—glaucoma	3.28e-05	0.000205	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—MMP1—glaucoma	3.26e-05	0.000203	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NGF—glaucoma	3.24e-05	0.000202	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—VEGFA—glaucoma	3.22e-05	0.000201	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—VEGFA—glaucoma	3.16e-05	0.000197	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—BCL2L1—glaucoma	3.16e-05	0.000197	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CYP1B1—glaucoma	3.15e-05	0.000196	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—ABCA1—glaucoma	3.15e-05	0.000196	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—TXN—glaucoma	3.14e-05	0.000196	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—CAV1—glaucoma	3.12e-05	0.000195	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CA2—glaucoma	3.12e-05	0.000195	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—C3—glaucoma	3.08e-05	0.000192	CbGpPWpGaD
Vemurafenib—BRAF—Disease—NOS3—glaucoma	3.07e-05	0.000191	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	3.05e-05	0.00019	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	3.05e-05	0.00019	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MTHFR—glaucoma	3.04e-05	0.00019	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MTHFR—glaucoma	3.02e-05	0.000188	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—FN1—glaucoma	2.97e-05	0.000185	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NGFR—glaucoma	2.9e-05	0.000181	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—APOE—glaucoma	2.87e-05	0.000179	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—APOE—glaucoma	2.87e-05	0.000179	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—BAD—glaucoma	2.86e-05	0.000178	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—GSTM1—glaucoma	2.86e-05	0.000178	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CAV1—glaucoma	2.84e-05	0.000177	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—CAV1—glaucoma	2.84e-05	0.000177	CbGpPWpGaD
Vemurafenib—RAF1—Disease—APOE—glaucoma	2.83e-05	0.000177	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—APOE—glaucoma	2.81e-05	0.000175	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CAV1—glaucoma	2.81e-05	0.000175	CbGpPWpGaD
Vemurafenib—BRAF—Disease—PTGS2—glaucoma	2.81e-05	0.000175	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CAV1—glaucoma	2.78e-05	0.000174	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—TNF—glaucoma	2.76e-05	0.000172	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NTRK1—glaucoma	2.76e-05	0.000172	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—FN1—glaucoma	2.7e-05	0.000169	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—BAD—glaucoma	2.67e-05	0.000167	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CDKN1B—glaucoma	2.66e-05	0.000166	CbGpPWpGaD
Vemurafenib—RAF1—Disease—BAD—glaucoma	2.64e-05	0.000165	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CA1—glaucoma	2.63e-05	0.000164	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—BAD—glaucoma	2.62e-05	0.000163	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—TXN—glaucoma	2.6e-05	0.000162	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CTSA—glaucoma	2.55e-05	0.000159	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CDKN2B—glaucoma	2.54e-05	0.000159	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—MTHFR—glaucoma	2.53e-05	0.000158	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—GSTM1—glaucoma	2.52e-05	0.000157	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EDN1—glaucoma	2.44e-05	0.000152	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GSTT1—glaucoma	2.44e-05	0.000152	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CA2—glaucoma	2.41e-05	0.00015	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—TP53—glaucoma	2.39e-05	0.000149	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—NOS3—glaucoma	2.36e-05	0.000147	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—APOE—glaucoma	2.35e-05	0.000147	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—CAV1—glaucoma	2.33e-05	0.000145	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NGF—glaucoma	2.24e-05	0.00014	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—MTHFR—glaucoma	2.22e-05	0.000139	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—TXN—glaucoma	2.2e-05	0.000137	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NOS3—glaucoma	2.15e-05	0.000134	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—C3—glaucoma	2.13e-05	0.000133	CbGpPWpGaD
Vemurafenib—RAF1—Disease—NOS3—glaucoma	2.12e-05	0.000132	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—NOS3—glaucoma	2.1e-05	0.000131	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—APOE—glaucoma	2.07e-05	0.000129	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CAV1—glaucoma	2.05e-05	0.000128	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GSTT1—glaucoma	2.01e-05	0.000126	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—glaucoma	2.01e-05	0.000125	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CDKN1B—glaucoma	1.99e-05	0.000124	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—glaucoma	1.99e-05	0.000124	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—APOE—glaucoma	1.98e-05	0.000124	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CAV1—glaucoma	1.97e-05	0.000123	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	1.97e-05	0.000123	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CYP1B1—glaucoma	1.94e-05	0.000121	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ABCA1—glaucoma	1.94e-05	0.000121	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PTGS2—glaucoma	1.94e-05	0.000121	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PTGS2—glaucoma	1.92e-05	0.00012	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—FN1—glaucoma	1.87e-05	0.000117	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CDKN1B—glaucoma	1.86e-05	0.000116	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—BAD—glaucoma	1.85e-05	0.000115	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CDKN1B—glaucoma	1.84e-05	0.000115	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CDKN1B—glaucoma	1.82e-05	0.000114	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—NOS3—glaucoma	1.76e-05	0.00011	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MMP9—glaucoma	1.72e-05	0.000108	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GSTT1—glaucoma	1.7e-05	0.000106	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—VEGFA—glaucoma	1.7e-05	0.000106	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—TXN—glaucoma	1.7e-05	0.000106	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PTGS2—glaucoma	1.61e-05	0.000101	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP1B1—glaucoma	1.6e-05	0.0001	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ABCA1—glaucoma	1.6e-05	0.0001	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GSTM1—glaucoma	1.55e-05	9.69e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—NOS3—glaucoma	1.55e-05	9.68e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—VEGFA—glaucoma	1.55e-05	9.66e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NOS3—glaucoma	1.49e-05	9.28e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PTGS2—glaucoma	1.42e-05	8.85e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	1.37e-05	8.58e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—MTHFR—glaucoma	1.37e-05	8.56e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ABCA1—glaucoma	1.36e-05	8.47e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP1B1—glaucoma	1.36e-05	8.47e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTT1—glaucoma	1.32e-05	8.21e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CDKN1B—glaucoma	1.29e-05	8.04e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TP53—glaucoma	1.28e-05	8.02e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GSTM1—glaucoma	1.28e-05	8e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—APOE—glaucoma	1.28e-05	7.97e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CAV1—glaucoma	1.27e-05	7.9e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MMP9—glaucoma	1.19e-05	7.44e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TP53—glaucoma	1.17e-05	7.3e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—MTHFR—glaucoma	1.13e-05	7.07e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GSTM1—glaucoma	1.09e-05	6.78e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—VEGFA—glaucoma	1.07e-05	6.68e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—APOE—glaucoma	1.05e-05	6.58e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ABCA1—glaucoma	1.05e-05	6.54e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP1B1—glaucoma	1.05e-05	6.54e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CAV1—glaucoma	1.04e-05	6.52e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—MTHFR—glaucoma	9.6e-06	5.99e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—NOS3—glaucoma	9.57e-06	5.97e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—APOE—glaucoma	8.93e-06	5.57e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CAV1—glaucoma	8.85e-06	5.52e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTGS2—glaucoma	8.75e-06	5.46e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTM1—glaucoma	8.38e-06	5.23e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TP53—glaucoma	8.09e-06	5.05e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—NOS3—glaucoma	7.9e-06	4.93e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—MTHFR—glaucoma	7.41e-06	4.62e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTGS2—glaucoma	7.23e-06	4.51e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—APOE—glaucoma	6.9e-06	4.3e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CAV1—glaucoma	6.83e-06	4.26e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NOS3—glaucoma	6.69e-06	4.18e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTGS2—glaucoma	6.12e-06	3.82e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NOS3—glaucoma	5.17e-06	3.22e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTGS2—glaucoma	4.72e-06	2.95e-05	CbGpPWpGaD
